1. Home
  2. PNNT vs ALXO Comparison

PNNT vs ALXO Comparison

Compare PNNT & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PennantPark Investment Corporation

PNNT

PennantPark Investment Corporation

HOLD

Current Price

$4.55

Market Cap

285.3M

Sector

Finance

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$1.63

Market Cap

240.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PNNT
ALXO
Founded
2007
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
285.3M
240.8M
IPO Year
2007
2020

Fundamental Metrics

Financial Performance
Metric
PNNT
ALXO
Price
$4.55
$1.63
Analyst Decision
Hold
Strong Buy
Analyst Count
5
4
Target Price
$5.75
$3.50
AVG Volume (30 Days)
654.6K
1.2M
Earning Date
05-07-2026
05-08-2026
Dividend Yield
21.05%
N/A
EPS Growth
N/A
26.36
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.14
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.29
$0.41
52 Week High
$7.53
$2.66

Technical Indicators

Market Signals
Indicator
PNNT
ALXO
Relative Strength Index (RSI) 45.25 37.98
Support Level $4.40 $1.60
Resistance Level $4.75 $2.30
Average True Range (ATR) 0.11 0.15
MACD 0.03 -0.01
Stochastic Oscillator 38.75 26.09

Price Performance

Historical Comparison
PNNT
ALXO

About PNNT PennantPark Investment Corporation

Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: